A molecular and preclinical comparison of the PD-1 –targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
T-cell checkpoint inhibition has a profound impact on cancer care and the programmed cell death protein 1 (PD-1) –targeted antibodies nivolumab and pembrolizumab have been two of the lead molecules of this therapeutic revolution. Their clinical comparability is a highly relevant topic of discussion, but to a significant degree is a consequence of their molecular properties. Here we provide a molecular, precl inical, and early clinical comparison of the two antibodies, based on the available data and recent literature.
Source: Seminars in Oncology - Category: Cancer & Oncology Authors: Petros Fessas, Hassal Lee, Shinji Ikemizu, Tobias Janowitz Source Type: research
More News: Cancer | Cancer & Oncology